Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nicole Melet

Physician Assistant, Medical San Francisco, CA Physician Assistant

NPI 1477657971 CMS profile 11050262

3838 California St Rm 610, San Francisco, CA 94118

Open in the dashboard

General payments

$18,891

801 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Melet of San Francisco, CA is reported in the CMS Open Payments database as having received $18,891 across 801 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,459 175
2024 General $5,749 211
2023 General $4,135 177
2022 General $2,827 156
2021 General $1,721 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Melet
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Nicole Melet were reported at $4,459. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Nicole Melet Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,721 $156 $41–$563 $132
2022 $2,827 $185 $55–$649 $149
2023 $4,135 $199 $58–$717 $160
2024 $5,749 $206 $62–$740 $164
2025 $4,459 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $3,512 165 payments
  2. AbbVie, Inc. $3,440 129 payments
  3. LEO Pharma Inc. $2,633 151 payments
  4. Lilly USA, LLC $1,535 52 payments
  5. Genzyme Corporation $1,466 42 payments
  6. Sun Pharmaceutical Industries Inc. $765 27 payments
  7. Regeneron Healthcare Solutions, Inc. $695 25 payments
  8. Pfizer Inc. $692 28 payments
  9. Incyte Corporation $558 32 payments
  10. UCB, Inc. $529 21 payments
  11. Other $3,064 129 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $18,397 788 payments
  2. Education $484 12 payments
  3. Travel and Lodging $9 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $3,072 127 payments
  2. ADBRY $2,269 132 payments
  3. SKYRIZI $2,194 81 payments
  4. DUPIXENT $1,698 50 payments
  5. TALTZ $1,235 47 payments
  6. RINVOQ $976 27 payments
  7. SIMPONI ARIA $743 41 payments
  8. OLUMIANT $709 23 payments
  9. STELARA $593 40 payments
  10. REMICADE $593 40 payments
  11. Other $8,219 372 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

366

Median for Physician Assistant: 241

Drug cost

$53,559

Median for Physician Assistant: $4,110

Branded share of claims

7.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 12 $42,540
Ciclopirox Generic 58 $2,077
Fluorouracil Generic 37 $1,967
Desonide Generic 35 $1,418
Sulfacetamide Sodium Generic 13 $1,213
Clobetasol Propionate Generic 27 $901
Ketoconazole Generic 54 $860
Metronidazole Generic 14 $653
Triamcinolone Acetonide Generic 46 $521
Doxycycline Hyclate Generic 25 $513

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$97,998

Of which drugs: $2,551

Medicare patients

337

Average age 76

Services billed

2,454

178 women, 159 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 38%
Diabetes 19%
Cancer 19%
Ischemic heart disease 18%
Osteoporosis 17%
Depression 14%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 97 $63

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$969 12 —
SKYRIZI
$870 — —
TREMFYA
$825 — —
ADBRY
$711 — —
OLUMIANT
$288 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

801 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record